Novartis India Ltd Share Price Results

Stocks

Novartis India Ltd Share Price

Results

Quarterly results

Show figures in :

Quarterly results

Quarter ended on March 31, 2025Data in Crores of INR

Revenue

₹ 83.88+3.34% from last year

Operating profits

₹ 34.54+59.69% from last year

Net income

₹ 29.30+99.59% from last year

Financial reports

Data is unavailable

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Net worth	784.96	744.82	775.66	691.70	711.19	720.73	759.19	733.64	919.64	1193.58
Fixed assets	4.54	6.94	19.25	23.65	63.91	76.28	14.98	4.60	5.71	6.48
Debt	-	0.02	-	-	-	-	-	-	-	-

View detailed balance sheet

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Operating	74.57	113.40	44.80	38.67	-69.21	-23.14	-194.28	160.99	-40.83	56.59
Investing	-3.31	33.13	-153.25	87.04	95.16	55.91	274.23	68.70	423.64	-630.47
Financing	-64.15	-120.99	-30.48	-35.63	-36.80	-41.41	-29.82	-267.65	-331.80	-38.57

Financial ratios

Profitability ratios info2

ROA5.35%

ROE13.19%

ROCE17.15%

EPS40.88%

Net profit margin28.32%

Operating profit margin34.19%

Dividend per share25%

Operational ratios info2

Quick ratio2.32%

Current ratio2.42%

Interest coverage170.38%

Assets turnover0.21%

Debt to equity

Valuation ratios info2

P/E ratio26.09%

P/B ratio

Dividend yield2.34%

EV/EBITDA

Novartis India Limited is a pharmaceutical company. The business operations of the Company include Pharmaceuticals Generic over the counter (OTC) and Animal Health. The Pharmaceuticals segment consists of a portfolio of prescription medicines which are provided to patients through healthcare professionals. The Generics segment consists of retail generics products. The Generics segment’s unit primarily focuses on the therapeutic segments such as Anti-TB Anti-DUB (Gynaecology) Anti-histamines Antibiotics Anti-ulcerants Anti-diabetes and Cardiovascular. The Animal Health segment has a presence primarily in the cattle and poultry market segments. The OT C segment is mainly in the vitamins minerals and nutritional supplements (VMS) and cough cold and allergy (CoCoA) market segments. During the fiscal year ended March 31 2012 it introduced Enplus product in the Poultry segment and Dexbov Antifur Vayuhara Vetimam and Feedavit in the Cattle segment..The company also in the business activities of OTC Generics Animal Health Pharmaceuticals.

Grow your wealth with more research recommendations

+91

To visit the old Ventura website, click here.

Ventura Wealth Clients Login here

Quarterly results

Quarterly results

Financial reports

Financial ratios

Grow your wealth with more research recommendations

Corporate Address